| Attributs | Valeurs |
|---|
| type
| |
| Is Part Of
| |
| Subject
| |
| Title
| - ▼Clopidogrel and ▼ticlopidine - improvements on aspirin?
|
| has manifestation of work
| |
| Abstract
| - ▼Clopidogrel (Plavix - Sanofi Winthrop/Bristol-Myers Squibb) and ▼ticlopidine (Ticlid - Sanofi Winthrop) are inhibitors of platelet function and are promoted as potential alternatives to aspirin. Clopidogrel is licensed for the secondary prevention of vascular events in patients with established atherosclerotic disease.1 The manufacturer claims that clopidogrel is "significantly more effective at reducing myocardial infarction, stroke and vascular death" compared to aspirin. Ticlopidine is licensed as an alternative to aspirin for secondary prevention of stroke and coronary complications in patients with intermittent claudication.2 However, in the UK, ticlopidine is more commonly used with aspirin to prevent complications following insertion of coronary stents during angioplasty. We consider whether the claims for clopidogrel and the current use of ticlopidine are justified.
|
| article type
| |
| publisher identifier
| |
| Alternative Title
| - ▼Clopidogrel and ▼ticlopidine - improvements on aspirin?
|
| is part of this journal
| |
| PubMed ID
| |
